Pursuing Optimal Therapy Remains a Challenge in Indolent B-Cell Lymphoma
October 25th 2021A significant proportion of patients worldwide live disease-free for a decade or longer following first-line therapy, with various approaches suggesting that there may be pathways to develop approaches for a cure for at least a subset of patients